jRCT2031210708招募中不适用
Phase I study of CBA-1535
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 70
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized Controlled Trial
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •ECOG performance status: <= 1
- •Patients with 3 months or longer life expectancy
排除标准
- •Patients who received other investigational drug or antibody drugs, including immune checkpoint inhibitor within 28 days prior to enrollment
- •Patients who received anti-cancer drug within 14 days prior to enrollment
结局指标
主要结局
-
- Dose Limiting Toxicity - Adverse Event
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Phase I study of CBA-1535JPRN-jRCT2031210708Tanaka Miseri70
招募中
1 期
Phase I study of CBA-1205JPRN-jRCT2080225288Chiome Bioscience Inc.41
进行中（未招募）
不适用
Protocol CA180015: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib MesylateEUCTR2004-002517-36-ITBRISTOL-M.SQUIBB
招募中
不适用
ONO-4915-01:ONO-4915 Phase I study
A study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ONO-4915 in Japanese healthy adult malesjRCT2071240056Ono Pharmaceutical Co.,LTD160
招募中
不适用
A phase 1 study to evaluate the BA/FE of S-337395 tablets in adults, and safety in elderly participantsjRCT2031240405Shionogi & Co., Ltd.130